Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

Author(s): Harika Modugula and Anoop Kumar*

Volume 19, Issue 2, 2020

Page: [109 - 114] Pages: 6

DOI: 10.2174/1871527319666200303120147

Price: $65

Abstract

Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression. However, emerging reports have indicated various adverse drug reactions with the use of lurasidone. Thus, in this article, we have analyzed the risk profile of lurasidone in the established therapeutic indication. A total of 419 studies were published from October 2010-July 2019 regarding lurasidone. After the inclusion and exclusion criteria, 17 studies were selected for the analysis of risk. The adverse drug reactions (ADRs) of these studies were categorized as per the innovator summary of product characteristics (SmPC). Finally, the unlisted ADRs were analyzed by using the Naranjo probability algorithm. Telogen effluvium, thrombocytopenia, restless leg syndrome and hypersexuality were found with the use of lurasidone and fall under the unlisted category. The causality assessment has shown a probable correlation of lurasidone with hypersexuality, restless leg syndrome, thrombocytopenia and possible relation with telogen effluvium. In conclusion, lurasidone is a novel and efficacious pharmacological treatment for bipolar depression and schizophrenia. However, more data regarding the safety of this drug in a large population is needed.

Keywords: Lurasidone, adverse drug reactions, schizophrenia, bipolar disorder, depression, dystonia.

Next »
Graphical Abstract

[1]
de Souza TB, Farias DM, Coletti RF, et al. Systemic administration of antipsychotic asenapine pre or postnatal does not induce anxiety-like behaviors in mice. CNS Neurol Disord Drug Targets 2018; 16(10): 1127-33.
[http://dx.doi.org/10.2174/1871527317666171213162403] [PMID: 29237385]
[2]
Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. A New schizophrenia model: immune activation is associated with the induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions. CNS Neurol Disord Drug Targets 2019; 18(2): 124-40.
[http://dx.doi.org/10.2174/1871527317666181119115532] [PMID: 30451122]
[3]
Gerasimou C, Tsoporis JN, Siafakas N, et al. A Longitudinal study of alterations of S100B, sRAGE and fas ligand in association to olanzapine medication in a sample of first episode patients with schizophrenia. CNS Neurol Disord Drug Targets 2018; 17(5): 383-8.
[http://dx.doi.org/10.2174/1871527317666180605120244] [PMID: 29875007]
[4]
Kanchanatawan B, Maes M. The Effects of tryptophan catabolites on negative symptoms and deficit schizophrenia are partly mediated by executive impairments: results of partial least squares path modeling. CNS Neurol Disord Drug Targets 2018; 17(6): 473-86.
[http://dx.doi.org/10.2174/1871527317666180702160921] [PMID: 29968545]
[5]
Dincin J. The biological basis of mental illness. New Dir Ment Health Serv Fall 2001; 91: 47-56.
[http://dx.doi.org/10.1002/yd.23320019106]
[6]
World Health Organization. Mental Health: New Understanding. Geneva: New Hope 2002.
[7]
Healy-Stoffel M, Levant B. N-3 (Omega-3) fatty acids: effects on brain dopamine systems and potential role in the etiology and treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2018; 17(3): 216-32.
[http://dx.doi.org/10.2174/1871527317666180412153612] [PMID: 29651972]
[8]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Press Inc. 2013.
[9]
Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: treatment options. Can J Psychiatry 1997; 42(2)(Suppl. 2): 87S-91S.
[PMID: 9288441]
[10]
Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 2013; 9: 1521-9.
[PMID: 24143101]
[11]
Belmaker RH. Lurasidone and bipolar disorder. Am J Psychiatry 2014; 171(2): 131-3.
[http://dx.doi.org/10.1176/appi.ajp.2013.13091240] [PMID: 24170243]
[12]
Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther 2011; 33(12): B40-8.
[http://dx.doi.org/10.1016/j.clinthera.2011.11.020] [PMID: 22177379]
[13]
Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets 2018; 17(10): 723-7.
[http://dx.doi.org/10.2174/1871527317666180828120256] [PMID: 30152291]
[14]
Sagman D, Tohen M. Comorbidity in bipolar disorder. Psychiatr Times 2009; 26(4): 1-9.
[PMID: 19000640]
[15]
Bawa R, Scarff JR. Lurasidone: a new treatment option for bipolar depression-a review. Innov Clin Neurosci 2015; 12(1-2): 21-3.
[PMID: 25852975]
[16]
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171(2): 169-77.
[http://dx.doi.org/10.1176/appi.ajp.2013.13070985] [PMID: 24170221]
[17]
Bruijnzeel D, Yazdanpanah M, Suryadevara U, Tandon R. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opin Pharmacother 2015; 16(10): 1559-65.
[http://dx.doi.org/10.1517/14656566.2015.1058780] [PMID: 26111577]
[18]
Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013; 225(3): 519-30.
[http://dx.doi.org/10.1007/s00213-012-2838-2] [PMID: 22903391]
[19]
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171(2): 160-8.
[http://dx.doi.org/10.1176/appi.ajp.2013.13070984] [PMID: 24170180]
[20]
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[21]
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52(6): 377-84.
[http://dx.doi.org/10.1136/jech.52.6.377] [PMID: 9764259]
[22]
SmPC of lurasidone from electronic medical compendium. Available at https://www.medicines.org.uk/emc/product/7551/smpc# UNDESIRABLE_EFFECTS Accessed on July 20th 2019.
[23]
Reddy B, Das S, Ali M. A Case of hypersexuality probably associated with lurasidone. J Clin Psychopharmacol 2018; 38(5): 537-9.
[http://dx.doi.org/10.1097/JCP.0000000000000934] [PMID: 30106878]
[24]
Ghori AK, Sajatovic M, Tampi RR. A Case of emergent restless legs syndrome with lurasidone therapy. J Clin Psychopharmacol 2016; 36(3): 293-4.
[http://dx.doi.org/10.1097/JCP.0000000000000496] [PMID: 27035496]
[25]
Rafi M, Goyal C, Reddy P, Reddy S. Lurasidone induced thrombocytopenia: is it a signal of drug induced myelosuppression? Indian J Psychol Med 2018; 40(2): 191-2.
[PMID: 29962579]
[26]
Benjamin J, Anand V. Need hair: pinpointing the cause of a patient’s hair loss. Curr Psychiatr 2018; 17(7): 52-3.
[27]
Tibrewal P, Bastiampillai T, Okungu A. Lurasidone-induced dystonia. Prim care companion CNS Disord 2017; 19(3): 16l02053.
[http://dx.doi.org/10.4088/PCC.16l02053]
[28]
Reichenberg JL, Ridout KK, Rickler KC. Lurasidone induced rabbit syndrome. J Clin Psychiatry 2017; 78(5): e553
[http://dx.doi.org/10.4088/JCP.16cr11157] [PMID: 28570801]
[29]
Mohanty R, Das B. Trunkal tardive dyskinesia due to lurasidone-a case report. Indian J Psychiatry 2018; 60(5): 157-7.
[30]
Kanzawa M, Hadden O. Case report of a switch to mania induced by lurasidone. Ther Adv Psychopharmacol 2017; 7(2): 91-3.
[http://dx.doi.org/10.1177/2045125316677954] [PMID: 28255439]
[31]
Doan LA, Williams SR, Takayesu A, Lu B. Case series reports on lurasidone-associated mania. J Clin Psychopharmacol 2017; 37(2): 264-6.
[http://dx.doi.org/10.1097/JCP.0000000000000655] [PMID: 28225748]
[32]
Lee M, Marshall D, Saddichha S. Lurasidone-associated neuroleptic malignant syndrome. J Clin Psychopharmacol 2017; 37(5): 639-40.
[http://dx.doi.org/10.1097/JCP.0000000000000774] [PMID: 28806387]
[33]
Sood S. Neutropenia with multiple antipsychotics including dose dependent neutropenia with lurasidone. Clin Psychopharmacol Neurosci 2017; 15(4): 413-5.
[http://dx.doi.org/10.9758/cpn.2017.15.4.413] [PMID: 29073755]
[34]
Kolli V, Walia A, Kinnan S. Food matters: reduction of lurasidone-induced nausea with meals. J Neurosci Rural Pract 2019; 9(3): 446-8.
[http://dx.doi.org/10.4088/PCC.18l02343]
[35]
Das S, Andi BS. Severe extrapyramidal syndrome caused by lurasidone low dose. J Neurosci Rural Pract 2018; 9(3): 446-8.
[http://dx.doi.org/10.4103/jnrp.jnrp_571_17] [PMID: 30069116]
[36]
Tripathi R, et al. Lurasidone HCL induced tardive dyskinesia: two cases. Reactions Weekly 2018; 1713: 226.
[http://dx.doi.org/10.1007/s40278-018-50060-6]
[37]
Das S, Agrawal A. Lurasidone-induced oculogyric crisis. Indian J Psychol Med 2017; 39(5): 719-20.
[http://dx.doi.org/10.4103/IJPSYM.IJPSYM_266_17] [PMID: 29200583]
[38]
Suthar N, Aneja J. Lurasidone-induced Parkinsonism and hyperprolactinemia. Indian J Psychol Med 2019; 41(2): 192-4.
[http://dx.doi.org/10.4103/IJPSYM.IJPSYM_274_18] [PMID: 30983673]
[39]
Hafeez ZH. Exanthematous rash with lurasidone in an elderly woman with schizoaffective disorder. Prim Care Companion CNS Disord 2019; 21(2): 18l02370.
[http://dx.doi.org/10.4088/PCC.18l02370]

Rights & Permissions Print Cite
Article Metrics
42
3
© 2024 Bentham Science Publishers | Privacy Policy